TR-987 vs. Placebo Following Fractionated CO2 Laser Resurfacing of the Chest

Exposure Laser Clinical Trial

Official title: TR-987 vs. Placebo Following Fractionated CO2 Laser Resurfacing of the Chest

Status Completed

Clinical Trial Summary

A single site, double-blind, randomized, placebo-controlled, clinical study comparing the difference between a novel healing gel and a placebo gel on post laser-resurfacing chests.

Clinical Trial Description

This is a double-blind, randomized, placebo-controlled, chest clinical study with a single study site. Forty subjects will receive fractionated CO2 laser resurfacing of the chest. . Immediately following the procedure (Day 0), postoperative gel randomized to the chest (TR-987 or placebo), will be applied with a thickness of 1-2 mm by a non-blinded coordinator, along with a split-chest Silon TSR bandage. Subjects will return for follow up on Day 1, with the gel and split chest Silon TSR© bandages applied by non-blinded coordinator during visit, with further follow-up on Days 6, 8, 10, 13 and 28. Both subjects and evaluating investigator will be blinded to randomization schedule (performed by an unblinded coordinator). Subject will apply gels and split chest Silon TSR© bandages at home on Days 2, 3 and 4 when not visiting clinic. ;

Related Conditions & MeSH terms

• Exposure Laser

• NCT number: NCT02681224
• Study type: Interventional
• Source: Goldman, Butterwick, Fitzpatrick and Groff
• Status: Completed
• Phase: N/A
• Start date: September 2015
• Completion date: January 2017